MarketCap
Facebook
X
TelegramGeschäftsbericht 2020
hinzugefügt 16.12.2023
Burford Capital Limited Operativer Cashflow 2011-2026 | BUR
Operativer Cashflow Jährlich Burford Capital Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 181 M | -8.31 M | -233 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 181 M | -233 M | -20.3 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-67.5 M | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
9.96 B | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 217.82 | -1.83 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
-23.6 M | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.35 | 0.3 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-176 M | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
175 M | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
-75.6 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
-348 M | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Dyadic International
DYAI
|
-6.73 M | $ 0.89 | -5.85 % | $ 25.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-85.9 M | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |